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Abstract
Background: Despite improved policies to prevent mother-to-child HIV transmission (MTCT), adherence to
maternal antiretroviral therapy (ART) and infant Nevirapine prophylaxis (NVP) is low in South Africa. We describe
ART adherence amongst a cohort of HIV-positive mothers and HIV-exposed but uninfected infants from 6 weeks
until 18 months post-delivery and identify risk factors for nonadherence.
Methods: Data were collected in 2012–2014 through a nationally representative survey of PMTCT effectiveness.
Mother-infant pairs were enrolled during the infant’s first immunization visit at 6 weeks. Mothers and HIV-exposed
infants (2811 pairs) were followed to 18 months at 3-month intervals. Mothers who self-reported being on ART at 6
weeks postpartum (N = 1572 (55.9%)) and infants on NVP at 6 weeks (N = 2370 (84.3%)) were eligible for this analysis
and information about their adherence was captured at each interview they attended thereafter. We defined
nonadherence within each 3-month interval as self-report of missing > 5% of daily ART/NVP doses, estimated
adherence using a Cox survival curve with Andersen & Gill setup for recurring events, and identified risk factors for
nonadherence with an extended Cox regression model (separately for mothers and infants) in Stata 13. Results are
not nationally representative as this is a subgroup analysis of the follow-up cohort.
Results: Amongst mothers on ART at 6 weeks postpartum, cumulative adherence to maternal ART until 18months
was 63.4%. Among infants on NPV at 6 weeks postpartum, adherence to NVP was 74.5%.. Risk factors for nonadherence
to maternal ART, controlling for other factors, included mother’s age (16–24 years vs. ≥34 years, adjusted Hazard Ratio
(aHR): 1.9, 95% CI: 1.4–2.5), nondisclosure of HIV status to anyone (nondisclosure vs. disclosure: aHR: 1.7, 95% CI: 1.3–2.1),
and timing of ART initiation (initiated ART after delivery vs. initiated ART before delivery: aHR: 1.6, 95% CI: 1.3–2.0).
Provincial variation was seen in nonadherence to infant NVP, controlling for other factors.
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Conclusion: Maintaining ART adherence until 18months postpartum remains a crucial challenge, with maternal ART
adherence among the six week maternal ART cohort below 65% and infant NVP adherence among breastfeeding
infants in this cohort below 75%.This is gravely concerning, given the global policy shift to lifelong ART amongst
pregnant and lactating women, and the need for extended infant prophylaxis amongst mothers who are not virally
suppressed. Our findings suggest that young mothers and mothers who do not disclose their status should be
targeted with messages to improve adherence, and that late maternal ART initiation (after delivery) increases the risk of
maternal nonadherence.
Keywords: HIV-exposed infants, Postnatal care, Missed visits
Introduction
Since the introduction of triple antiretroviral treatment
(ART) and extended infant prophyaxis by national-level
programs to prevent mother to child transmission of
HIV (PMTCT) each new generation of infants in Sub-
Saharan Africa has been born with lower prevalence of
HIV than the last [1, 2]. Highly active antiretroviral
treatment (ART) preserves a mother’s overall health, re-
duces her viral load, and reduces risk of MTCT, while
Nevirapine (NVP) as infant HIV prophylaxis prevents in-
fection in HIV-exposed infants [3, 4]. Global gains in
PMTCT have reduced transmission such that numerous
countries imminently face elimination of maternal to
child transmission of HIV (eMTCT)- achieving genera-
tions born HIV-free [5, 6].
Despite these gains, an estimated 122,000 children
under the age of 15 years acquired HIV infections in
sub-Saharan Africa in 2015, most of which were due to
MTCT [7]. South Africa remains the country with the
highest number of people living with HIV (PLHIV) in
the world, 6.4 million PLHIV [8], accounting for 18% of
global HIV prevalence [9]. HIV prevalence among
women reporting to public health facilities for antenatal
care (ANC) is high at 29.7% in 2013 [10], demonstrating
the magnitude of the PMTCT program required to
maintain low MTCT in South Africa.
South Africa has aggressively adopted the World Health
Organization’s (WHO) increasingly rigorous guidelines
for PMTCT since introducing a national PMTCT pro-
gram in 2002 [11, 12]. Impressively, South Africa reduced
early MTCT at 4–8 weeks postpartum from 9% in 2009 to
2.6% (95% CI 2.0–3.2) in 2012–2013 [13].
Under WHO Option A and Option B (adopted in
April 2013), all HIV-positive pregnant and breastfeeding
women were entitled to ART for life if eligible by a CD4
count less than 350 cells/mm3. Under Option A, preg-
nant women with a CD4 count over 350 cells/mm3 were
eligible for ART prophylaxis from 14 weeks gestation
until 7 days postpartum. HIV-exposed infants received
daily NVP from birth to 7 days after cessation of breast-
feeding or through age 4–6 weeks if the mother was not
breastfeeding. Under Option B, pregnant women with a
CD4 count over 350 cells/mm3 were eligible for triple
ART from 14 weeks gestation through 7 days after cessa-
tion of breastfeeding and all HIV-exposed infants were
provided daily NVP through age 4–6 weeks regardless of
feeding method [14, 15]. In December 2014, South Af-
rica adopted Option B+ entitling all HIV positive preg-
nant and lactating women ART for life regardless of
clinical indicators [16]. With these efforts, more than
91% of HIV-positive mothers in South Africa received
ART or prophylaxis in 2014 [17].
Despite high coverage of the PMTCT program and
successful reduction in MTCT, the first HIV-free gener-
ation in South Africa will only be possible once factors
influencing ongoing MTCT are alleviated. One such fac-
tor - nonadherence to ART among mothers and infants
from pregnancy to cessation of breastfeeding - poses a
particular threat to MTCT rates by reducing viral sup-
pression and enabling transmission [18]. By understand-
ing the magnitude of nonadherence to ART among
mothers and infants and the risk factors for nonadher-
ence, we can inform programmatic shifts to reduce non-
adherence and MTCT.
Nonadherence is difficult to measure as it often relies
on information that is self-reported by a patient. Concerns
remain about the validity of self-reported adherence mea-
sures due to memory biases which often overestimate
adherence [19]. However, several studies substantiate
these measures as appropriate for estimating adherence to
ART in developing settings [20, 21]. While there is no
gold standard metric [22], ART adherence between 80
and 99% is critical to maintain viral suppression, reduce
risk of developing drug resistance, and reduce risk of
MTCT [23]. Much of the literature regarding ART adher-
ence, sets the threshold for adherence as achieving at least
95% of prescribed daily doses since this is required for op-
timal health outcomes [24]. The analyses herein utilize
self-reported information to assess 95% adherence to ART
among mothers and infants.
We describe longitudinal, self-reported adherence to
ART among HIV-positive mothers and to Nevirapine
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among their HIV-exposed infants at 3-month intervals
from 6 weeks to 18months postpartum within a sub-
group of the follow-up cohort for PMTCT evaluation.
Further, we identify risk factors for nonadherence with
the goal of informing improvements to PMTCT pro-
gramming that support ART adherence among mother-
infant pairs.
Methods
Study design and population
This study was a secondary analysis of data collected to
evaluate the effectiveness of the national programme to
prevent HIV transmission from mother to child in South
Africa. The evaluation was a nationally-representative
cross-sectional survey conducted in 2012/13 (October
2012–May 2013), with infant follow-up until September
2014. Public sector health facilities were sampled using
multi-stage, probability proportional to size method-
ology using three strata per province based on 6 week
client immunization load and antenatal HIV prevalence.
The study was powered to produce nationally-represen-
tative results of MTCT at 6 weeks. More detailed
information about the survey is available in previous
publications [11, 13].
Mother-infant pairs were enrolled into the study dur-
ing the infant’s first postpartum immunization visit at 6
weeks as national coverage for this first postpartum
immunization visit is known to be over 60% in surveyed
areas of South Africa [25]. If the infant was deemed HIV
exposed but uninfected at the 6 week cross-sectional
visit, mother-infant pairs [N = 2811] were eligible and
consented for a further cohort survey involving three-
monthly follow-up, from 3 until 18 months. The primary
outcomes of this 3-to-18 month national cohort will be
presented in a separate publication.
Data and blood collection
Trained nurse fieldworkers interviewed mothers or non-
mother caregivers at the 6 week immunization visit and
follow-up visits conducted at 14 weeks and six, nine,
twelve, fifteen, and 18 months postpartum about socio-
demographic information, infant health and feeding
practices, maternal understanding of MTCT, HIV test-
ing, postnatal care, and maternal and infant PMTCT
prophylaxis and treatment. Approximately 375 μl of
blood per infant was drawn and dropped onto five pre-
printed circles on Munktell TFN filter paper to deter-
mine infants HIV exposure and infection. Visual aids
such as pictures of ARV pills and ARV syrup bottles
were used to assist mothers in identifying the type of
regimen received. A feeding and medication diary was
issued to mothers so they could document medication
received, and to assist with recall of missed daily doses
during interviews. Non-mother caregivers were not
asked questions about maternal health and/or HIV test-
ing and treatment.
Data analysis
Two analyses were conducted: Maternal ART adherence
(ART analysis) amongst mothers eligible for analysis and
infant nevirapine (NVP) adherence (NVP analysis)
amongst HIV-exposed infants eligible for analysis.
Mothers were eligible for inclusion in the ART analysis
if they were included in the follow-up cohort of 2811
mother-infant pairs and indicated that they were on
ART at 6 weeks post-delivery (N = 1572). At each fol-
low-up interval thereafter at 14 weeks, 6, 9, 12, 15, and
18months postpartum, information about ART adher-
ence was included in the analysis for mothers (not other
caregivers) who attended that particular interview and
were still taking ART.
Infants were eligible for inclusion in the NVP analysis
if they were HIV-exposed, included in the follow-up co-
hort of 2811 mother-infant pairs and were reported to
be on infant NVP at the six week visit, (N = 2370).
Thereafter, information about NVP adherence was
included in the analysis for breastfeeding infants who
attended that particular interview and were still on NVP.
Mothers and infants who were removed from ART or
NVP based on national guidelines were not further ana-
lyzed for adherence in this analysis.
Nonadherence to ART among mothers and NVP
among infants was defined as reporting taking less than
95% of daily doses within each three month follow-up
interval. For mothers and infants, this was operational-
ized in two scenarios where some mothers/infants were
deemed non-adherent because they had failed to take
ART/NVP for more than 5% of the daily doses in that
interval, while others were non-adherent because they
had ceased taking ART/NVP within the interval without
professional advice. We assumed that medical advice to
stop NVP was provided in compliance with national
guidelines (therefore indicating adherence). We assumed
other reasons for stopping NVP were not in compliance
guidelines (therefore indicating nonadherence).
For mothers or infants who reported missing more than
5% of daily doses, failure date was calculated as the mid-
point of the interview interval. For infants who stopped
taking NVP during an interval, their age in weeks at NVP
cessation was used to calculate date of failure.
Mothers were excluded from the adherence analysis at
a particular time point if they had missed an interview
during the interval of interest or a non-mother caregiver
had responded to the interview, thus information about
the mother’s adherence was not provided. Infants were
no longer included in the analysis if breastfeeding had
been stopped in the prior interval, thus removing the
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threat of transmission and the need for NVP per
PMTCT guidelines.
We performed frequency analyses to describe charac-
teristics of the mothers and infants and their care. To
describe probability of ART or NVP adherence from 6
weeks to 18 months postpartum we plotted extended
Cox model survival curves using the stcox and stcurve
commands in Stata [26, 27] after preparing the data for
Andersen-Gill time-to-event analysis for recurring
events [28, 29]. The Andersen-Gill model is a counting
process allowing assessment of multiple nonadherence
events across follow-up intervals instead of censoring on
the first instance of nonadherence [28, 30, 31].
We fitted multivariable Andersen-Gill extended Cox
models to determine risk factors for ART nonadherence
among mothers and infants separately. Andersen-Gill
models generalize the Cox proportional hazards model,
accommodating the non-proportionality of the effect of
covariates in the case of recurrent failure events [31].
The resulting coefficients are a measure of all-cause ef-
fects across multiple recurrent events as demonstrated
in other studies describing risk factors associated with
recurring health events [32–35].
Covariates of interest from the information collected
at 6 weeks were identified a priori. We used the forward
stepwise function to fit the models from these covariates,
setting the significance level for addition to the model at
15% and removal from the model at 20% [30]. The pro-
portional hazards assumption was upheld for both
models which we assessed by running a model that in-
cluded time-varying covariates. All analyses were per-
formed in STATA 13.1. Because this is a subgroup
analysis of the cohort of mothers followed up by the
study, the results are not nationally representative.
Therefore, results are not adjusted for the study design,
non-response and not weighted for live-births.
Ethical consideration
The protocol was reviewed according to the Centers for
Disease Control and Prevention (CDC) human research
protection procedures and was determined to be re-
search, but CDC was not engaged. The protocol was also
reviewed by the institutional review board of the Medical
Research Council of South Africa. Mothers and care-
givers provided written informed consent prior to the
onset of the interview and assent for infants to undergo
blood collection.
Results
Characteristics of study population
The majority of the mothers in the study population
were between 25 and 34 years old (ART analysis: 59.2%,
NVP analysis: 56.3%). Three quarters of the mothers in
both samples were educated up to grade 8–12. Most
mothers were single (ART analysis: 70.8%, NVP analysis:
73.9%) (Table 1).
At the six week interview, most mothers reported a
main source of income other than their own employ-
ment such as a child support grant, disability grant, a
partner or husband’s support, or another family mem-
ber’s support (ART analysis: 77.9%, NVP analysis:
80.6%). Over a third of infants (37.3%) were breastfed
between birth and 6 weeks. Less than half of the mothers
had planned pregnancies (ART analysis: 40.3%, NVP
analysis: 37.1%).
Adherence to antiretroviral treatment among mothers
and infants
Cumulative probability of adherence to ART until 18
months postpartum was 63.4% among mothers included
in the ART analysis (95% confidence interval (CI): 60.7–
66.0) and 74.5% among infants included in the NVP ana-
lysis (95% CI: 70.2–81.9) (Fig. 1, Table 2). From 6 weeks
to 14 weeks postpartum, adherence to NVP was 96.4%
among infants (95% CI: 94.3–97.8). From 6 weeks to 14
weeks postpartum, ART adherence was lower amongst
mothers at 85.0% (95% CI: 82.8–87.0). Cumulative infant
NVP adherence was consistently higher than mother
ART adherence over the 6 weeks to 18months postpar-
tum period.
Among both mothers and infants, a higher proportion
of nonadherence events were due to stopping treatment
not according to national guidelines (range: ART ana-
lysis: 73.9–88.4%, NVP analysis: 58.3–100%) rather than
missing at least 5% of daily doses (range: ART analysis:
15.2–26.2%, NVP analysis: 0–41.7%) (Table 2).
Risk factors of nonadherence to ART among mothers
Maternal age influenced ART adherence from 6 weeks
to 18 months postpartum with adolescents and young
women (aged 16–24 years) having a higher hazard of
nonadherence events during that period than women
over 34 (age 16–24, adjusted Hazard Ratio (aHR): 1.9,
95% CI 1.4–2.5).
Failing to disclose one’s HIV positive status to anyone
at baseline was a risk factor for nonadherence (aHR: 1.7,
95% CI: 1.3–2.1). Not knowing one’s CD4 result also
increased risk of nonadherence among mothers.
Compared to mothers with a known CD4 result, those
who had a CD4 test done but results were not received
(aHR: 1.3, 95% CI: 1.1–1.6) or it was not known if CD4
test was done (aHR: 2.1, 95% CI: 1.4–3.2) were at higher
risk for nonadherence.
Mothers who initiated ART after delivery were at
higher risk for nonadherence (aHR: 1.6, 95% CI: 1.3–2.0)
than those who initiated ART before delivery. Mothers
who delivered their infants outside of health facilities
had almost double the hazard of nonadherence than
Larsen et al. BMC Infectious Diseases 2019, 19(Suppl 1):789 Page 4 of 13
Table 1 Characteristics of mothers (N = 1572) on ART at 6 weeks postpartum and infants (N = 2370) on NVP at 6 weeks postpartum
among a cohort in South Africa in 2012–2014
Characteristics Mothers on ART at 6 weeks
N = 1572
Infants on NVP at 6 weeks
N = 2370
N (%) N (%)
MATERNAL CHARACTERISTICS
Maternal age
16–24 years 298 (19.0) 619 (26.1)
25–34 years 931 (59.2) 1334 (56.3)
35+ years 343 (21.8) 417 (17.6)
Education of mother
Grades 1–7 297 (18.9) 410 (17.3)
Grades 8–12 1196 (76.1) 1827 (77.1)
Tertiary 53 (3.4) 94 (4.0)
None/DK/NA 26 (1.6) 39 (1.6)
Marital status
Single 1113 (70.8) 1751 (73.9)
Married 295 (18.8) 395 (16.7)
Co-habiting 151 (9.6) 207 (8.7)
Widowed 10 (0.6) 13 (0.6)
Divorced/separated 3 (0.2) 4 (0.2)
Province
Northern Cape 60 (3.8) 76 (3.2)
Limpopo 148 (9.4) 233 (9.8)
Eastern Cape 143 (9.1) 206 (8.7)
Free State 222 (14.1) 301 (12.7)
Gauteng 312 (19.9) 471 (19.9)
KwaZulu Natal 252 (16.0) 407 (17.2)
Mpumalanga 151 (9.6) 266 (11.2)
North West 139 (8.9) 201 (8.5)
Western Cape 145 (9.2) 209 (8.8)
Primary source of income
Othera 1225 (77.9) 1910 (80.6)
Own employment 347 (22.1) 460 (19.4)
Parity
One child 323 (20.6) 562 (23.7)
2–3 children 983 (62.5) 1453 (61.3)
4+ children 266 (16.9) 355 (15.0)
Transport to clinic
Walk 892 (56.7) 1309 (55.2)
Taxi/Bus/Train 603 (38.4) 956 (40.3)
Own vehicle 68 (4.3) 89 (3.8)
Other 9 (0.6) 16 (0.7)
Time to reach clinic (minutes)
0–30 min 1280 (81.4) 1919 (81.0)
> 30min 292 (18.6) 451 (19.0)
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those who delivered at a facility (aHR: 1.9, 95% CI: 1.2–
3.0), however only 43 mothers delivered outside of the
facility.
Parity and whether the pregnancy was planned were
included in the model but were not significantly associ-
ated with nonadherence.
Table 1 Characteristics of mothers (N = 1572) on ART at 6 weeks postpartum and infants (N = 2370) on NVP at 6 weeks postpartum
among a cohort in South Africa in 2012–2014 (Continued)
Characteristics Mothers on ART at 6 weeks
N = 1572
Infants on NVP at 6 weeks
N = 2370
N (%) N (%)
PREGNANCY AND CONTINUUM OF CARE
Planned pregnancy
No 936 (59.5) 1491 (62.9)
Yes 633 (40.3) 879 (37.1)
DK/NA 3 (0.2) 0 (0.0)
Timeliness of first ANC visit
> 12 weeks 1030 (65.5) 1589 (67.1)
≤ 12 weeks 542 (34.5) 781 (32.9)
ANC Visits
< 4 visits 156 (9.9) 286 (12.1)
4+ visits 1416 (90.1) 2084 (87.9)
Delivery care location
Hospital 1246 (79.3) 1830 (77.2)
Clinic 283 (18.0) 456 (19.3)
Home/other 43 (2.7) 84 (3.5)
PNC Visits
< 3 visits 1269 (80.7) 1885 (79.5)
3+ visits 303 (19.3) 485 (20.5)
Ever breastfed infant in first 6 weeks
No 1005 (63.9) 1485 (62.7)
Yes 567 (36.1) 885 (37.3)
HIV TESTING AND TREATMENT FACTORS
HIV status disclosed to family and/or friends
No 177 (11.3) 400 (16.9)
Yes 1395 (88.7) 1970 (83.1)
Aware of CD4 cell count
CD4 test done and result received 1037 (65.9) 1519 (64.1)
CD4 test not done 49 (3.1) 119 (5.0)
CD4 test done, result not received 441 (28.1) 668 (28.2)
Do not know if had CD4 test 45 (2.9) 64 (2.7)
Ever heard of PMTCT
No 192 (12.2) 288 (12.2)
Yes 1380 (87.8) 2082 (87.8)
Initiated ART after delivery
No 599 (38.1) 691 (29.1)
Yes 783 (49.8) 1457 (61.5)
Don’t know/Chose not to answer 190 (12.1) 222 (9.4)
a Other primary sources of income include: Child support grant, disability grant, partner/husband/ex-husband, other family member
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Risk factors of nonadherence to Nevirapine among
infants
Provincial variation in NVP nonadherence in the 6 week
to 18 month postpartum period was seen in the infant
population with those in Northern Cape, North West,
Western Cape, and Eastern Cape experiencing the high-
est hazard of nonadherence compared to those in Free
State (Northern Cape, aHR: 5.3, 95% CI: 1.9–14.8; North
West, aHR: 4.8, 95% CI: 1.8–12.6; Western Cape, aHR:
4.1, 95% CI: 1.4–11.7; Eastern Cape: aHR: 3.2, 95% CI:
1.1–9.3) (Table 3).
Infants whose mothers had not heard of PMTCT prior
to the six week interview had higher hazard of nonad-
herence within the 6 week to 18 month postpartum
period than those whose mothers had heard of PMTCT
(aHR: 1.6, 95% CI: 0.9–32.8; p value < 0.10), although
this was not significant at 5%. Not knowing the mother’s
partner’s HIV status showed increased hazard for nonad-
herence (aHR: 1.4, 95% CI: 10.9–2.1; p value < 0.10) but
this was not significantly at 5%. Maternal parity was in-
cluded in the model but was not significantly associated
with adherence.
Discussion
Adherence to antiretroviral treatment among mothers
and infants until 18 months postpartum
This study observed suboptimal ART adherence until 18
months postpartum among this cohort of HIV-positive
mothers and infants, with below 65% of mothers and
below 75% of infants cumulatively maintaining adherence
over 95% from 6weeks to 18months postpartum. This is
gravely concerning, given the global policy shift to lifelong
ART amongst pregnant and lactating women, and the
need for extended infant prophylaxis amongst mothers
who are not virally suppressed. We found ART adherence
to be higher at earlier time points, with both mothers and
infants over 85% adherent by 14 weeks over or about 80%
by 6months. A similar analysis of infant ART adherence
in Zambia showed a lower adherence until 6 months of
about 70% (versus our result of 93.0%), and until 18
months of just above 0% (versus our result of 73.4%) [36].
A study from Malawi showed lower maternal ART adher-
ence than our study, with 75% adherence by 3months,
about 50% adherence by 6months, and under 40% adher-
ence by 18months [37]. While the study in Malawi used a
pharmacy-based adherence measure, our study utilized
self-reported adherence which tends to overestimate ad-
herence due to recall bias and social desirability. This may
account for the differences in adherence seen across these
two studies. Results from a systematic review of adherence
among women on ART in low- middle- and high-income
countries reported adherence of 53% (95% CI: 33–73) dur-
ing the postnatal period, although the timeframe was not
specifically defined [4]. While our results from this cohort
of mothers and infants indicate higher ART adherence
than that seen in similar studies from the region, possibly
because of the Hawthorne effect [38] as a result of three-
monthly follow-up by nurses, adherence reported herein
Fig. 1 Adherence to ART among a cohort of mothers (N = 1572) and NVP among a cohort of infants (N = 2370) at 6 weeks, in South Africa and
followed-up at 3-month intervals from 6 weeks to 18 months postpartum in 2012–2014 (unweighted)
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remains suboptimal to eliminate MTCT and highlights
room for improvement on the implementation of PMTCT
guidelines [5, 24].
Infant adherence was higher than mother adherence
by about 10% across the entire 6 weeks to 18months
postpartum period. This may suggest that efforts made
by the mother to ensure adherence within the mother-
infant pair are prioritized toward the infant’s HIV
prophylaxis adherence over her own HIV treatment.
Risk factors of nonadherence to ART among mothers
We identified risk factors for nonadherence to inform
further improvements to PMTCT programming. Adoles-
cents and young women in this cohort (age 16–24 years)
had a higher hazard of nonadherence than women older
than 25, consistent with similar studies about PMTCT
and maternal and child health seeking [39–41]. A study
from Uganda indicates that this is potentially due to lack
of knowledge and experience with childbirth and health,
as well as age-related discrimination from the heath sys-
tem [42]. In South Africa, adolescent girls and young
women have particularly high risk for acquiring HIV in-
fection and low uptake of HIV services [43]. Targeted
HIV interventions to increase HIV prevention and
service coverage among this high risk group were initi-
ated in South Africa in 2015.
Initiating ART after delivery was a risk factor for non-
adherence among mothers, indicating that initiation on
Table 2 Frequency of nonadherence types per interval and cumulative probability of adherence to ART among a cohort of mothers
(N = 1572) and NVP among a cohort of infants (N = 2370) from 6 weeks to 18 months postpartum in South Africa followed in 2012–
2014 (unweighted)













Adherence to ART among mothers reported on ART
Total number of mothers entering interval n = 1026 n = 902 n = 866 n = 833 n = 800 n = 832












Total adherence events during interval 861 820 801 777 749 763
Total nonadherence events during interval 165 82 65 56 51 69
Taking ART but missed > 5% doses 25 (15.2) 17 (20.7) 17 (26.2) 9 (16.1) 8 (15.7) 8 (11.6)
Stopped taking ART during interval
(not according to care)
140 (84.8) 65 (79.3) 48 (73.8) 47 (83.9) 43 (84.3) 61 (88.4)
Mothers not included in the analysis at each stage and reason for exclusion
Total number of mothers not reporting on ART at interval n = 546 n = 670 n = 706 n = 739 n = 772 n = 740
Missed interview 462 (84.6) 508 (75.8) 528 (74.8) 544 (73.6) 542 (70.2) 473 (63.9)
Non-mother caregiver gave interview 84 (15.4) 92 (13.7) 94 (13.3) 111 (15.0) 150 (19.4) 185 (25.0)
No longer on ART 0 (0.00) 70 (10.5) 84 (11.9) 84 (11.4) 80 (10.4) 82 (11.1)
Adherence to NVP among infants reported on NVP
Total number of infants assessed for adherence in interval n = 1145 n = 702 n = 426 n = 248 n = 125 n = 52












Total adherence events during interval 1102 670 403 236 113 49
Total nonadherence events during interval 43 32 23 12 12 3
Taking ART but missed > 5% doses 8 (18.6) 12 (37.5) 5 (21.7) 3 (25.0) 5 (41.7) 0 (0.0)
Stopped taking NVP during interval (not according to care) 35 (81.4) 20 (62.5) 18 (78.3) 9 (75.0) 7 (58.3) 3 (100.0)
Infants not included in the analysis during each interval and reason for exclusion
Total number of infants not reporting on NVP
at interval
n = 1225 n = 1668 n = 1944 n = 2122 n = 2245 n = 2318
Missed interview 338 (27.6) 405 (24.3) 437 (22.5) 448 (21.1) 425 (18.9) 389 (16.8)
Appropriately stopped NVP 887 (72.4) 1263 (75.7) 1507 (77.5) 1674 (78.9) 1821 (81.1) 1929 (83.2)
Never breastfed during interval 850 (95.8) 1183 (93.7) 1404 (93.2) 1542 (92.1) 1678 (92.2) 1784 (92.5)
Clinician said to stop NVP 37 (4.2) 80 (6.3) 103 (6.8) 132 (7.9) 143 (7.8) 145 (7.5)
aSurvivor function (probability of adherence) is calculated over full data and evaluated at indicated times; it is not calculated from aggregates shown in this table
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Table 3 Unadjusted and adjusted risk factors for nonadherence to ART among a cohort of mothers and NVP among a cohort of




Cox proportional hazard model
Characteristic Unadjusted (95% CI) p value Adjusted (95% CI) p value
hazard ratio hazard ratio
Maternal age
35+ years 1 1
25–34 years 1.21 0.96–1.54 0.111 1.21 0.95–1.54 0.123
16–24 years 1.93 1.46–2.53 0.000 1.87 1.42–2.47 0.000
Delivery care location
Hospital/clinic 1 1
Home/other 1.61 1.03–2.53 0.036 1.87 1.19–2.94 0.007
CD4 result received
CD4 test done and result received 1 1
CD4 test not done 1.43 0.88–2.34 0.150 1.34 0.82–2.20 0.242
CD4 test done, result not received 1.33 1.10–1.62 0.004 1.28 1.06–1.57 0.012
Do not know if had CD4 test 2.56 1.73–3.80 0.000 2.15 1.44–3.20 0.000
HIV status disclosed to family and/or friends
Yes 1 1
No 1.69 1.33–2.14 0.000 1.67 1.31–2.12 0.000
Planned pregnancy
Yes 1 1
No 1.25 1.04–1.51 0.017 1.18 0.98–1.42 0.082
No response 2.14 0.30–15.27 0.448 2.54 0.35–18.28 0.356
Initiated ART after delivery
No 1 1
Yes 1.66 1.36–2.03 0.000 1.61 1.31–1.96 0.000




Cox proportional hazard model
Characteristic Unadjusted 95% CI p-value Adjusted 95% CI p-value
hazard ratio hazard ratio
Province
Free State 1 1
Limpopo 1.30 0.35–4.86 0.693 1.31 0.35–4.89 0.689
Eastern Cape 2.97 1.01–8.68 0.047 2.97 1.01–8.73 0.048
Northern Cape 5.27 1.92–14.44 0.001 5.16 1.86–14.28 0.002
Gauteng 1.23 0.40–3.75 0.719 1.25 0.41–3.82 0.701
KwaZulu Natal 1.97 0.68–5.66 0.210 2.02 0.70–5.85 0.192
Mpumalanga 2.58 0.89–7.42 0.079 2.48 0.86–7.17 0.093
Northwest 4.86 1.85–12.79 0.001 4.81 1.82–12.72 0.002
Western Cape 4.28 1.48–12.32 0.007 3.95 1.37–11.41 0.011
Maternal parity
One child 1 1
2–3 children 1.26 0.74–2.13 0.394 1.07 0.62–1.82 0.817
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ART earlier in the continuum of care may be an import-
ant protective measure to improve adherence. The
current national guidelines entitling all HIV positive
pregnant and breastfeeding women to lifelong ART par-
tially address this concern [5]. Additionally, messaging
that encourages timely attendance to antenatal care
visits among pregnant women in South Africa may
increase early initiation on ART [44].
Knowledge of one’s CD4 count protected mothers from
nonadherence, indicating that compliance with CD4 test-
ing and returning of test results to patients may have con-
tributed to improved adherence to ART among mothers.
At the time of these data, ART initiation was based on
CD4 count< 350 under Option B guidelines, therefore for
mothers who were not experiencing symptoms and there-
fore did not feel the pressing need for ART adherence,
CD4 results may have offered a motivating factor [45, 46].
Counseling messages from health providers received with
CD4 test results could have improved a mother’s under-
standing of the importance of ART adherence to PMTCT,
thus reducing nonadherence [47]. This confusion around
CD4 count is no longer an anticipated barrier at the
present era of test and treat for life.
Disclosure of HIV status to family and friends was
protective from nonadherence within this cohort, as
seen in other studies from South Africa and other sub-
Saharan African settings [48–50]. These studies postu-
lated that the psychosocial support gained through
disclosure, as well as the accountability to one’s treat-
ment, encourage adherence. PMTCT programmatic
messages should encourage mothers to disclose their
HIV status to improve ART adherence. Furthering the
case for support as a protective factor against nonad-
herence is the result that married and cohabitating
mothers showed lower nonadherence than single, di-
vorced, and widowed women.
Mothers who delivered their infants in health facilities
had lower hazard of nonadherence than those who
delivered outside of a formal health facility. We postu-
late that this is due to additional support provided when
a delivery is in a health facility. Other studies have found
that individuals exhibiting high health seeking behavior
have been found to have higher adherence to ART [51].
Messages about the importance of ART adherence for
PMTCT are provided whenever a mother interacts with
the health system along the continuum of care [12], thus
those delivering in a facility receive a higher frequency
of these messages.
Adjusted risk factors of nonadherence to Nevirapine
among infants
Provincial variation in nonadherence may be indicative
of inconsistencies in effectiveness of PMTCT, potentially
explained by a complex network of differences in relative
strength of the provincial health systems, messaging sur-
rounding the importance of PMTCT, the general status
of health, and geography. As a highly dynamic and mi-
gratory population, variation in health seeking behavior
is expected, as noted in other studies [17, 43, 52].
Limitations
By nature of the population followed until 18 months
postpartum by the national PMTCT Evaluation study,
the present study did not include adherence for HIV-ex-
posed infants who had a positive PCR result at 6 weeks
or their mothers. As a cohort analysis observing a sub-
group from this follow-up population, the results were
not adjusted for the study design, non-response and not
weighted for live-births, thus limiting the representative-
ness of these results.
The Andersen-Gill extended cox proportional hazards
model selected for this analysis requires a strong statis-
tical assumption of independence across the increments
in which nonadherence events can occur [35]. This
assumes that a nonadherence event is not influenced by
a prior nonadherence event within a study participant.
Thus, event dependence is not included in the model.
Without strong evidence to support dependence across
nonadhernece events, we chose this model.
Table 3 Unadjusted and adjusted risk factors for nonadherence to ART among a cohort of mothers and NVP among a cohort of
infants in South Africa followed in 2012–2014 identified with cox proportional hazards model (unweighted) (Continued)
4+ children 1.68 0.90–3.16 0.106 1.45 0.76–2.75 0.259
Mother ever heard of PMTCT
Yes 1 1
No 1.76 1.01–3.06 0.044 1.70 0.96–3.00 0.068
Mother knows partner’s HIV status
Yes 1 1
No 1.48 0.98–2.24 0.061 1.46 0.97–2.21 0.072
aMothers were included in survival analysis if they were on ART at 6 weeks and had information about ART adherence at any follow-up visit
bInfants were included in survival analysis if they were on NVP at birth and had information about NVP adherence at any follow-up visit
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ART adherence was evaluated on self-reported
responses, therefore issues of false reporting and recall
likely biased the results, however we cannot determine
whether these are under- or over-estimates. To
minimize such information bias we checked road-to-
health cards to verify maternal self-report of HIV status
and ART uptake. The consistency between maternal self-
report of these measures and the record from the road-to-
health card increased our confidence in other self-reported
measures.
A high proportion of mothers and infants included in
the follow-up study missed interviews during the 18
month follow-up period. Due to the lack of information
about these participants at intervals where the interview
was missed, participants were not included in the ana-
lysis for any missed interval, likely introducing bias into
the results. There was no date of failure captured for
mothers who stopped taking ART during an interval,
thus the midpoint was used which could have under- or
over-estimated the time contributed.
A higher probability of adherence during later analysis
time may been driven by loss to follow-up of non-adher-
ent women and may not reflect an actual improvement
in adherence, as women with poor adherence are at
higher risk of loss to follow-up than those with good ad-
herence [37, 53]. This mechanism of “informative cen-
soring” biases analysis of adherence patterns over time.
The population studied herein is highly dynamic [17,
54, 55], exemplified by the fact that individuals could
move in and out of the included study population at
each follow-up interval. Such mobility likely contributes
to the low adherence seen here, both by providing a bar-
rier to adherence among mothers and their infants and
by posing a challenge to measurement within our fol-
low-up interviews. The high proportion of missed inter-
views underscores the importance of strengthening
counseling to ensure that individuals understand the im-
portance of ART adherence to viral suppression, redu-
cing risk of MTCT, and reducing risk of drug resistance.
Mothers were continually counseled on the importance
of adherence to health outcomes throughout the course
of the study, especially when non-adherence events were
identified.
Conclusion
Our findings from this cohort of mothers and infants in
South Africa suggest that suboptimal adherence to ART
for PMTCT persists, which likely contributes to
remaining mother-to-child HIV transmission events. Re-
sults from this cohort of mothers and infants in South
Africa suggest that young mothers are an important tar-
get for the PMTCT national program with messages
stressing the importance of adherence; all pregnant
women and mothers need support to disclose their HIV
status to loved ones, to deliver in a facility, and to know
their CD4 count to improve ART adherence. Addition-
ally, a mother’s knowledge of PMTCT and knowledge of
her partner’s HIV status could improve infant adherence
to Nevirapine.
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